Decreased initiation of usual activities in people with mild-to-moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial

被引:24
|
作者
Cook, Cheryl [3 ,4 ]
Fay, Sherri [3 ,4 ]
Rockwood, Kenneth [1 ,2 ]
机构
[1] Dalhousie Univ, Div Geriatr Med, Halifax, NS B3H 2E1, Canada
[2] Capital Dist Hlth Author, Div Geriatr Med, Halifax, NS, Canada
[3] Capital Dist Hlth Author, Geriatr Med Res Unit, Halifax, NS, Canada
[4] Dalhousie Univ, Geriatr Med Res Unit, Halifax, NS B3H 2E1, Canada
基金
加拿大健康研究院;
关键词
initiation; Alzheimer's disease; galantamine; phenomenology;
D O I
10.1017/S1041610208007230
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Decreased initiation of activities is a common symptom in Alzheimer's disease (AD) and creates significant burden for carers, yet little is known about how patients, carers and treating physicians describe this problem. Methods: This is a secondary, qualitative analysis of video-recorded, semi-structured and open-ended interviews with the 130 community-dwelling patients with mild-to-moderate AD from the Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) study - a four-month, randomized, placebo-controlled trial of galantamine. Interviews were coded and organized using Atlas.ti. By applying a framework analysis approach, patient/carer descriptions of dementia-related decreased initiation of usual tasks and activities were categorized and summarized. Results: Decreased initiation of instrumental activities of daily living (IADLs) and/or leisure and social activities was reported in 85/130 patients at baseline, 71 (84%) of whom specifically targeted increased initiation as a goal of treatment. The most common manifestations of decreased initiation were initiating only with prompting (55%), and no longer initiating but willing to engage in the activity (42%; note that these groups can overlap). Many patients were also described as having less interest (44%) or impaired performance (34%) in the activity in which decreased initiation was noted. Coping strategies were employed by 69/85 carers, most commonly verbal prompts to begin an activity. Conclusion: Decreased initiation is a common and problematic symptom in people with mild-to-moderate Alzheimer's disease who seek treatment for dementia. Information offered voluntarily about interest in or ability to perform activities which are initiated less often gives additional data compared with routine questioning about initiation of function. This is a potentially rich area for the elucidation of disease and treatment effects.
引用
收藏
页码:952 / 963
页数:12
相关论文
共 50 条
  • [41] Gait speed, cognition and falls in people living with mild-to-moderate Alzheimer disease: data from NILVAD
    Adam H. Dyer
    Brian Lawlor
    Sean P. Kennelly
    BMC Geriatrics, 20
  • [42] Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab
    Russu, Alberto
    Samtani, Mahesh N.
    Xu, Steven
    Adedokun, Omoniyi J.
    Lu, Ming
    Ito, Kaori
    Corrigan, Brian
    Raje, Sangeeta
    Liu, Enchi
    Brashear, H. Robert
    Styren, Scot
    Hu, Chuanpu
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 53 (02) : 535 - 546
  • [43] Clinical Trial Design Issues in Mild to Moderate Alzheimer Disease
    Knopman, David S.
    COGNITIVE AND BEHAVIORAL NEUROLOGY, 2008, 21 (04) : 197 - 201
  • [44] Costs of care in a mild-to-moderate Alzheimer clinical trial sample: Key resources and their determinants
    Gustavsson, Anders
    Cattelin, Francoise
    Jonsson, Linus
    ALZHEIMERS & DEMENTIA, 2011, 7 (04) : 466 - 473
  • [45] Study Partner Type and Adverse Event Reporting in Mild-to-Moderate Alzheimer's Disease Clinical Trials
    Lu, Thuy V.
    Grill, Joshua D.
    Gillen, Daniel L.
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 98 (02) : 729 - 738
  • [46] Visual object and face processing in mild-to-moderate Alzheimer's disease: from segmentation to imagination
    Tippett, LJ
    Blackwood, K
    Farah, MJ
    NEUROPSYCHOLOGIA, 2003, 41 (04) : 453 - 468
  • [47] Nutritional Status and Dietary Intakes of The Patients With Mild-To-Moderate Alzheimer's Disease
    Fernando, Malika
    Marliya, Thasmeeha
    Raeesa, Fathima
    Williams, Shehan
    Silva, Renuka
    ANNALS OF NUTRITION AND METABOLISM, 2019, 75 : 294 - 294
  • [48] Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease
    M E Risner
    A M Saunders
    J F B Altman
    G C Ormandy
    S Craft
    I M Foley
    M E Zvartau-Hind
    D A Hosford
    A D Roses
    The Pharmacogenomics Journal, 2006, 6 : 246 - 254
  • [49] Correlating functional and cognitive decline in patients with mild-to-moderate Alzheimer's disease
    Feldman, H
    Kavanagh, S
    Van Baelen, B
    INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 257 - 258
  • [50] Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
    Salloway, Stephen
    Sperling, Reisa
    Fox, Nick C.
    Blennow, Kaj
    Klunk, William
    Raskind, Murray
    Sabbagh, Marwan
    Honig, Lawrence S.
    Porsteinsson, Anton P.
    Ferris, Steven
    Reichert, Marcel
    Ketter, Nzeera
    Nejadnik, Bijan
    Guenzler, Volkmar
    Miloslavsky, Maja
    Wang, Daniel
    Lu, Yuan
    Lull, Julia
    Tudor, Iulia Cristina
    Liu, Enchi
    Grundman, Michael
    Yuen, Eric
    Black, Ronald
    Brashear, H. Robert
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (04): : 322 - 333